Braeburn Pharmaceuticals and Camurus (STO:CAMX) touted data today from a long-term Phase III study of its weekly and monthly buprenorphine depots in patients with moderate-to-severe opioid use disorder.
The safety and efficacy study enrolled 228 patients and 71% of participants completed the 48-week treatment. The safety profile of CAM2038 was comparable to previous, shorter studies, according to the companies. No opioid overdoses were reported for patients treated with the buprenorphine depot injections.
Get the full story at our sister site, Drug Delivery Business News.
The post Braeburn, Camurus tout long-term phase III data for opioid addiction therapy appeared first on MassDevice.